One Sentence Summary: Systems Biology approach to find novel drug combinations that can promote injured axons in the adult rat optic nerve to regenerate long distances.
Introduction
Injury in the adult CNS is often permanent due to lack of ability of severed axons to regenerate. The inability to regenerate axons is attributed to two major causes: lack of intrinsic capacity of the CNS neurons in adult mammals to regenerate, and the presence of extracellular factors that inhibit axonal outgrowth (1) (2) (3) (4) . Myelin-associated molecules are thought to play a major role in inhibiting axonal regeneration (2, 5) . In addition to this extrinsic inhibition, lack of appropriate activation of intracellular signaling pathways is also thought to play a role. Prominent among these are the MTOR (6) and STAT3 (7) (8) pathways. Simultaneous inactivation of PTEN, an endogenous inhibitor of the MTOR pathway, and SOCS3, an endogenous inhibitor of the STAT3 pathway, led to robust and sustained axonal regeneration (9) . Recently it was shown that sustained activation of the MTOR pathway by genetic manipulation, when combined with visual stimulation, leads to extended regeneration of optic nerve axons such that they reach the brain (10) . Transcriptomic analyses of dorsal root ganglion (DRG) neurons following peripheral nerve injury have identified the potential involvement of numerous signaling pathways including neurotrophins, TGFβ cytokine, and JAK-STAT (11) . Using these transcriptomic data and the Connectivity MAP, these researchers identified the drug ambroxol, a Na + channel inhibitor that promoted axon regeneration after optic nerve crush in mice (11) . These observations suggest that drug therapy based on regulation of subcellular processes including cell signaling pathways could be a feasible approach to promote axon regeneration after nerve injury. We have been studying signaling through the Go/i pathway for over two decades and found that activated Gαo activates STAT3 to promote oncogenic transformation (12) . Studies of Neuro-2A cells treated with a cannabinoid receptor-1 (CB1R) agonist indicated that this receptor, acting through the GTPases Rap, Ral and Rac, activates Src and in turn STAT3 to stimulate neurite outgrowth (13) (14) . A more extensive study identified a complex upstream signaling network that controls STAT3 and CREB to regulate neurite outgrowth (15) . These studies indicated that multiple receptors could regulate STAT3 to drive neurite outgrowth. IL-6 had been shown to promote neurite outgrowth in a PC-12 variant, and to overcome myelin-mediated inhibitors to promote neurite outgrowth in primary neurons (7, 16) . We showed that submaximal, potentially therapeutic concentrations of the CB1R agonist HU-210 together with IL-6 could activate STAT3 in a sustained manner and induce neurite outgrowth in both Neuro2A cells and primary rat cortical neurons (17). Based on these observations we decided to test if a combination of these two drugs could promote axonal regeneration in vivo in the CNS in the rat optic nerve crush model.
In designing a potential combination therapy, we anticipated that stimulating signaling in the cell body of injured neurons alone probably would not lead to long-distance axon regeneration to the brain, and that we would need to modulate additional loci for extended axonal growth. Hence we sought to develop a systems-level combination therapy based on spatial specification of drug action. We identified drugs that could modulate subcellular function in the cell body and axon. We could then utilize this spatial information to develop a drug combination with the potential for treating CNS nerve injury by promoting long-range axonal regeneration. Since transcriptional regulation is critical for neurite outgrowth (15) , we reasoned that CB1R and IL6R actions are likely to be in the cell body. We looked for subcellular processes in the axon that could be potential drug targets, and utilized computational dynamical models of neurite outgrowth (18) to predict how different subcellular processes could promote axonal regeneration. Based on these simulations we focused on microtubule growth, which is required for axon regeneration. Microtubules are stabilized by taxol, which has been shown to promote axonal regeneration (19). As axonal regeneration is inhibited by cell remnants at the site of injury, we hypothesized that such inhibition could be due to the incorporation of membrane vesicles at the growth cone (20). Treating the site of injury to potentially clear it of inhibitory agents and reduce the inflammatory response could also contribute to axonal regeneration. Based on these considerations, we chose a protease that could act locally to reduce the debris field and inhibit inflammation. We selected APC, which is a serine protease endogenous to the coagulation system (21) that is thought to be anti-inflammatory, and which promotes neuronal repair by stem cells in mice (22). In another study we independently observed that APC can promote limited axonal regeneration of crushed optic nerve in rat (23) .
The overall logic for this four-drug combination is schematically shown in Fig. 1 . We decided to test if a combination of these drugs, two applied at the cell body and two at the axon at the site of injury, promoted long distance regeneration such that visual stimulation led to restoration of physiological function.
Results

Neurite outgrowth in microfluidic chambers with IL-6 and HU-210:
We previously found that submaximal concentrations of IL-6 and HU-210 in combination have an additive effect on neurite outgrowth for rat cortical neurons in primary culture (17). We tested if this effect could be observed for regeneration of growing neurites that had been severed in vitro. For these experiments we used microfluidic chambers, where the cell bodies could be compartmentalized from the growing axons ( Fig. 2Aa ). We plated primary rat cortical neurons on a permissive substrate in these chambers, and allowed them to grow long neurites. To mimic axotomy, we lesioned all the neurites in the chambers on the right side and then added HU-210 and IL-6 to one side or the other (Fig. 2Ab ). Application of IL-6 and HU-210 to the cell bodies (somal; left side of chamber) significantly promoted neurite growth up to 300 µm from the soma; in contrast, drug application to the axonal compartment was less effective, and offered no benefit when add to somal drug application ( Fig. 2A , c-d). We then repeated the experiment using myelin, a non-permissive substrate (Fig. 2B ). We observed that addition of IL-6 and HU-210 to the cell bodies promoted longer growth of axotomized processes in the presence of myelin, compared to either treatment alone.
We also examined the effects of IL-6 and HU-210 on neurite outgrowth in cortical neurons. When whole myelin was used as the substrate, IL-6 and HU-210 promoted neurite outgrowth, overcoming the inhibitory effect of myelin (Figs. 2C&D and Supplementary Fig. 1 ). As previously reported in Neuro2A cells (17), the combination of IL-6 and HU-210 in cortical neurons stimulated STAT3 by phosphorylation at Tyr705 ( Fig. 2E , and Supplementary Fig. 1 ), consistent with our earlier observation that HU-210-stimulated neurite outgrowth depends on Stat3-mediated transcription (17). We confirmed the presence of the receptors for IL-6 (gp130) and CB1(CB1R) in our cortical cultures by RT-PCR, as shown in Supplementary Fig. 2I . We also detected the receptors by immunolabeling, and found both gp130 and CB1R were expressed in the somal compartment of microfluidic chambers ( Supplementary Fig. 2II ). The combination of IL-6 and HU-210 did not significantly enhance neuronal survival after axotomy ( Supplementary Fig. 2III ).
Drug Treatment for Axonal Regeneration in vivo
To test whether treatment with HU-210 and IL-6 promotes axon regeneration following injury in vivo, we used the optic nerve crush (ONC) model in Fisher rats (24) . Following surgery, we treated the injured eye with HU-210 and IL-6 injected intravitreally, and after two weeks we evaluated for regeneration, first by sectioning the nerve and immunostaining with GAP-43 antibody (Figs. 3A&B). We observed a promoting effect of combined HU-210 and IL-6 treatment, the majority of the crushed axons without drug treatment had no detectable GAP-43 labeling even 0.2mm distal to the crush site, while intravitreal injections of a combination of HU-210 + IL-6 resulted in detectable axons nearly 3mm away from the crush site ( Fig. 3B ). In additional studies we visualized regenerating processes by labeling the axons with cholera toxin-B subunit (CTB) coupled to Alexa-488 (25) , chemically clearing the nerves using the 3-DISCO technique (26) , and obtaining maximum intensity projection images (Figs. 3C&D). The 3-DISCO technique allowed us to image the crush site from proximal to distal end, and to examine the Z-stack to confirm that the crush was complete with no spared fibers. To evaluate the efficiency of the crush method, we performed ONC with no drug treatment and CTB-labeled the nerves immediately afterwards. When we examined the nerve 3 days later, we observed complete crushes in the brightfield setting and the CTB-label was not detected past the crush site (Fig, 2F ). Moreover, we examined each nerve for evidence of any spared fibers; an example is shown in Supplementary Fig. 3A . Samples with such incomplete crushes were excluded from further analysis. In nerves from animals that received intravitreal injections of IL-6 & HU-210, we could observe CTB-labeled fibers over 2 mm from the crush site (Figs. 3D&D'). Fluorescence was quantified at 250-µm intervals from the crush site, revealing a striking difference between the treated and untreated groups (Fig. 3E ).
The effectiveness of HU-210 and IL-6 in the ONC model was confirmed in Long-Evans rats. Axonal regeneration was not observed in animals that received either no drug treatment or treatment with submaximal doses of intravitreally injected IL-6 or HU-210 individually, as assessed by CTB-labeled fibers 0.2 mm distal to the crush site ( Fig. 4A-C) . In contrast, the combination of intravitreal IL-6 and HU-210 resulted in significant axon growth, extending on average more than 0.5 mm beyond the crush site ( Fig. 2D ). While the effect of HU-210 + IL-6 was less pronounced than that observed in Fisher rats, subsequent experiments were restricted to Long-Evans rats because the albino phenotype of Fisher rats makes them unsuitable for retinal electrophysiology.
Our overall goal was to devise a drug therapy that would provide sufficient regeneration after the optic nerve crush so that we could restore communication between the eye and the brain. The observations here and our previous biochemical data (15, 17) indicate that the effects of HU-210 and IL-6, injected intravitreally, likely reflect upregulated biosynthetic processes. To promote more robust growth we decided to additionally apply drugs that could work at the injury site. We looked for additional subcellular processes that could be targeted by drugs. For this we utilized a dynamical model of neurite outgrowth that we have recently developed (18) that is focused on understanding how activities of groups of subcellular processes are balanced to produce a whole-cell response. In this computational model we had studied how microtubule growth and membrane vesicle transport and fusion at the growth cones are together responsible for neurite growth. These simulations indicated that simultaneously regulating microtubule dynamics and membrane vesicle dynamics could greatly enhance axon regeneration. Taxol is known to stabilize dynamic microtubules, leading to elongation of stable microtubules, and thus promotes axonal regeneration (19). To enhance membrane vesicle delivery-related subcellular processes, we focused on external inhibitors of axonal growth, including myelin-associated proteins such as Nogo. Biochemical experiments have shown that Nogo receptors and gangliosides mediate glycoprotein inhibition of neurite outgrowth (27) and binding of extracellular agents such as Nogo to gangliosides can promote endocytosis (28) , thus disrupting membrane delivery to the growth cone plasma membrane which is essential for continued growth of the axon. Since the site of injury contains many such myelin-related proteins, to relieve inhibition we decided to test the application of a protease that could act locally. For this we chose APC (activated protein C), which has been reported to promote neuronal repair (22). We used gel foam to apply taxol or APC to the site of injury, either alone or in combination with HU-210 and IL-6 applied at the cell body through intravitreal injection. Taxol alone in gelfoam had a modest effect on promoting some regenerating fibers as reported earlier ( Fig. 4E) (29) . APC alone promoted significant axonal regeneration about 0.5 mm past the crush site ( Fig. 4G ). The effect of APC was most prominent on one edge of the nerve, presumably where we had placed the drug-impregnated gelfoam (Fig. 4G ). In order to ascertain whether these were spared fibers, we carefully examined the crush site of this nerve treated with APC ( Supplementary Fig.  3C ) and observed that the crush was in fact complete, with regenerating CTB-labeled fibers growing along the edge of the nerve. Combining IL-6 and HU-210 with taxol gelfoam ( Fig 4F) produced a more robust response compared to the three agents individually or IL-6 and HU-210 combined, growing over 0.5 mm distal to the crush site. However, none of the drugs tested could promote extensive axonal regeneration individually. More extensive growth was observed when APC was combined with IL-6 and HU-210 ( Fig 4H) .
A 4-drug combination promotes optic nerve regeneration to the chiasm
We then tested a four-drug combination with intravitreal injection of HU-210 and IL-6 to deliver these agents to the retinal ganglion cell body, and application of taxol and APC in gelfoam at the site of injury. We sacrificed the animals after 3 weeks of drug treatment. Three days prior to euthanasia we intravitreally injected CTB in some animals to visualize the regenerated axons. The whole nerve was chemically cleared using the 3-DISCO technique (26) . In other animals, nerve sections were immunostained for GAP-43. We observed that 7 out 29 animals tested (5 with CTB-labeling and 2 with GAP-43 immunostaining) had regenerating axons that could be detected at the chiasm, a distance of 7.5 mm from the crush site ( Fig 5-IA,B ) Another four animals with the four-drug treatment combination showed modest axonal regeneration extending about 3 mm from the crush site (Table 1A) . Quantification of the extent of CTB label for each condition tested is provided in Supplementary Fig. 4 are maximum intensity projections using the 3-DISCO method of clearing, which are 2-D flattened generated images of approximately 540 Z-slices. We looked at individual slices within the same nerve (slice #240 and #274 out of 537, Supplementary Fig 5A&B) and found CTB-labeled fibers growing in torturous pattern from the crush and even 1mm away from the crush site, as highlighted in the closeups.
A number of additional experiments are shown in the Supplementary Figs. 4&5 to establish that what we observe are regenerated fibers. In Supplementary Fig. 3A, we show an example of an incomplete crush. With the 3-DISCO technology we could examine all the CTB-labeled axons in the nerve bundle, and we can observed spared fibers toward the bottom edge demarcated by an arrow. When we observed such a sample, the animal was disqualified from the study. In Supplementary Fig. 3B shows an uninjured nerve with CTB labeling, illustrating the full extent of fibers with the optic nerve bundle. We also waited 7days post CTB labeling ( Fig. 5-II) we detected robust axonal regeneration from the crush site ( Fig. 5 -IIB) into the chiasm (Fig. 5-IIC) . A close up view of the crush site is provided in Supplementary Fig 6A, with inverted image colors to show that our crushes are complete with no observable sparing. In the chiasm, we saw torturous growth of regenerating axons with CTB label as they grow into the chiasm from the injured side ( Fig. 5-IIC' ) and to the opposing side (Figs. 5-IIC" & C'"). In this particular animal we sectioned the contralateral brain and observed with immunostaining for CTB that there was label in superior colliculus, an area innervated by the optic nerve ( Fig. 5 -IID and close-up of the image in Fig. 5-III) .
In separate studies, using the iDISCO technique we labeled the whole nerve with antibodies against GAP-43 and then chemically cleared them (see Supplementary Fig. 7 ) (30) . Both CTBlabeled and GAP43-immunostained chemically cleared nerves were imaged using a multiphoton microscope. Supplementary Fig. 7 shows, the crush site where GAP-43 axons regenerated past the crush site (top panel), in close proximity to the chiasm (middle panel) the closeup box shows GAP-43+ staining ( Supplementary Fig. 7B') . The bottom panel we have GAP-43-labeled axons detected in the chiasm, as demarcated by the asterisks and in the closeup boxes (Supplementary Figs. 7C' and C'). All of these experiments provide additional support that the CTB-labeled nerves observed in Fig. 5 -I are regenerated axons.
Dynamical computational models indicate that relief of inhibition could be a mechanism underlying the extensive axonal regeneration.
To gain insight into the mechanism by which the four-drug combination promotes extensive regeneration, we modeled the effects of these drugs on neuronal growth processes. We used the top-down version of a neurite-outgrowth multicompartment ODE model that we developed previously (18). This model analyzes the dynamics of a whole-cell process in terms of interactions between three subcellular processes: Production of Membrane Components, Vesicle Transport and Exocytosis, and Microtubule Growth. This model is based on the microtubule growth model developed by Margolin et al. (31) and the vesicle transport model of Heinrich and Rapaport (32) . Our simulations show that the highly synergistic effects of the four drugs on axon growth can be quantitatively explained by assuming that a transcription-mediated increase in the biosynthesis of components required for axonal growth (by HU-210 and IL-6) such that molecular components needed for axonal growth are not limiting, combined with stabilization of growing microtubules by by taxol and removal of inhibitory extracellular factors by APC can suppress vesicle fusion at the growth cone. Relief of inhibition of vesicle fusion by APC greatly enhances the ability of the other three drugs to drive axonal regeneration resulting in apparent synergy. Key results from the computational modeling are shown in Supplementary Figures 11-13 . Details of the computational models are provided in the Supplementary Material (Computational Model of Drug Effects on Neurite Outgrowth).
The 4-drug combination treatment partially restores electroretinograms and cortical visual evoked potential in animals subjected to optic nerve crush
We tested if the morphologically observed axonal regeneration led to restoration of functional electrophysiological responses. Pattern electroretinograms (pERG) were recorded from both eyes of rats with one crushed optic nerve to determine if the four-drug combination could improve overall retinal electrophysiology, particularly of RGCs (33) (Fig. 6A ). In normal non-injured eyes, pERGs elicited by a full-field contrast-reversing grating are characterized by a small initial negative component approximately 35 ms after pattern reversal (N35), followed by a larger positive component between 45-60 ms (P50), and finally a large negative component at 90-100 ms (N95). However, the injured eye of control animals with only vehicle injections had an aberrant pERG, while injured animals that received the four-drug combination treatment showed partial pERG recovery in the injured eye. The recovery approached pre-injury responses for the P50 component. These observations indicate that the four-drug combination stabilizes the cell bodies of the injured retinal ganglion neurons leading to some recovery of electrophysiological function.
pERGs reflect the physiology of retinal neuronal cell bodies, but not of optic nerve axons themselves (33) . Since we obtained some degree of axonal regeneration into the brain with the four-drug treatment, we asked whether there is concomitant recovery of brain electrophysiological responses to visual stimuli. We stimulated each eye with a series of light flashes at different intensities (0.001 to 100% of maximum) and simultaneously recorded the flash ERG (fERG), which is indicative of activity in all neuronal cells of the retina (not just the RGC that innervates the optic nerve), and the visual evoked potential (VEP) detected bilaterally from the primary visual cortex. Figure 6B -D shows representative fERGs for light flashes to the uninjured eye ( Figure 6B ), the injured eye of a vehicle-treated animal ( Figure 6C ), and the injured eye of a drug-treated animal ( Figure 6D ). fERG signals were reduced at all intensities for injured with vehicle treatment relative to the uninjured control side, consistent with neurodegeneration that occurs due to the crush. The fERGs in animals that received the fourdrug treatment appeared nearly normal, indicating that the therapy was neuroprotective for injured retinal neurons. In Figure 6E , we show the VEP for flashes to the non-injured eye. The VEP is slow and monotonic at lower intensities (<0.1%) and becomes markedly faster and multiphasic at higher intensities. The VEP is absent for flashes to the injured eye of vehicletreated animals (Fig. 6F) . In contrast, VEPs were detected at high light intensities in a subset of animals that were treated with the four-drug combination (Fig. 6G) . The signal was slow and monotonic in these animals, similar to non-injured eyes at low light intensities. We performed statistical analysis on the VEP records by comparing them to traces recorded after weak flashes that yielded no apparent VEP, and setting a threshold for detectability (see Methods). We found that responses for all of the vehicle-treated animals (n = 7) were not significantly different from noise, even at the highest flash intensities. However, 5 of 19 drug-treated animals showed VEP responses above the cut-off criterion at some flash intensity ( Fig 6H and Table1B) , indicating partial restoration of functional connectivity in those animals. Data of VEP recordings for three individual animals for the non-injured eye, injured with vehicle only (no treatment), and injured with four-drug treatment are shown in Supplementary Figs. 8-10 .
Discussion
In this study, we designed a drug therapy for a complex pathophysiology by using systems-based logic. We considered the multiple subcellular processes occurring at different locations within the cell that could be involved in axonal regeneration, and identified drugs that could regulate these subcellular processes. We focused on drugs that would increase capacity for regeneration at the neuronal cell body, and enhance the ability of the axons to grow longer by modulating local subcellular processes in the axonal shaft. We made the assumption that the process of neurite outgrowth in vitro involves many if not all of the subcellular processes that neurons use regenerate axons in vivo. Cell signaling experiments in our laboratory had shown that transcriptional regulation through STAT3 and CREB played a major role in neurite outgrowth (12, 17) . Independent studies had shown a role for the cAMP pathway (2) and SOCS3, a STAT inhibitor (9) . Hence we reasoned that application of receptor ligands that stimulate the STAT3 pathway among other transcriptional regulators (15) could increase the intrinsic capacity of neurons to regenerate. Since CB-1 and IL-6 receptors are expressed in adult neurons, we selected agonists for these receptors as regenerative drugs. In vitro experiments showed that application of these drugs at the cell body was more effective in promoting regeneration, and hence in vivo we applied the drug at the cell body as well. As we used the optic nerve crush model, we injected the receptor agonists intravitreally so that they could act on the RGC cell bodies. This resulted in modest but significant drug-stimulated axon regeneration beyond the site of injury. These experiments provided us with an important guideline: that not only should we select the right subcellular process to target, but also that the drug should be applied at the right location. Using this reasoning we selected the two core sets of subcellular processes that function within the growing axon and could targeted by drugs: microtubule growth, and membrane expansion at the growth cone. Since taxol stabilizes dynamic microtubules, thus allowing axonal processes to grow, we applied taxol to the growing axonal regions. By integrating observations in the literature (27, 28) , we reasoned that the debris at the injury site including myelin-associated proteins might inhibit axonal growth by inhibiting the exocytotic delivery of membranes to the growth cone, which is needed for axonal growth. Hence, we selected a locally acting protease that could clear the debris field and block these inhibitory agents. Our experiments show that this combination of increasing capacity at the cell body and modulating subcellular processes in the growing axon enables substantial regeneration from the site of injury to the visual cortex, such that we were able to partially restore electrophysiological communication from the eye to the visual cortex. Our results provide an example of the systems therapeutic approach providing a rational basis for the design of therapies to treat complex pathophysiologies, in this case nerve damage in the CNS.
Although it is encouraging that we have an identifiable path for a systems logic-based design of rational therapeutics, much further work is needed to translate these findings into viable treatments even in animal models. We have not considered dosing regimens or adverse events associated with this drug therapy. We also need to establish the relationship between the extent of recovery of electrophysiological function and vision-dependent behaviors in the whole animal. These types of experiments will form the basis for future studies. Nevertheless, since observations in the optic nerve crush model are most often applied to spinal cord injury, it will be useful to test if this four-drug combination can reverse spinal cord injury and restore some movement. Note Tables 1A and B are two separate groups of animals.
Figure1: Spatial Systems Reasoning for Combinational Therapy to promote CNS axonal regeneration.
A. Diagrammatic cartoon of a neuron displaying the retinal ganglion cell body whose axon is crushed leading to axonal degeneration and severing connection to the brain. The axon will degenerate from crush site. B. Our four-drug combination delivery is to apply drugs to both the neuronal cell bodies and to the injury site. Two drugs injected intravitreally to the cell body -IL-6 and HU-210, which will bind to their respective receptors -IL-6R and CB1R, that will elicit a downstream signal to the nucleus to initiate transcription. Another two drugs will be administered in gelfoam to the injury site, where APC will contribute to overcome inhibitors in the injured environment and Taxol to stabilize injured microtubules. Figure 2A . Somal application of IL-6 and HU-210 results in enhanced neurite outgrowth after axotomy. Cortical neurons were plated in the somal compartment (blue) of microfluidic chambers, schematically represented in (Aa.) and allowed to grow axons across the microgrooves into the axonal compartment (red). The gray cone depicts a pipet used to perform axotomy by aspirating medium from the axonal compartment. (Ab.) For axotomy experiments, neurons were cultured in chambers on PLL for 6-7 days, and axotomy was performed by aspirating all medium from the axonal compartments 2-4 times.. 5 ng/ml IL-6 and 100 nM HU-210 were added together to the somal, axonal or both compartments after axotomy. Treatments were added to the indicated compartments in neurobasal (NB) immediately after axotomy, and neurons were imaged live after 24 hrs using Calcein AM. (Ac.) Representative confocal images after axotomy and treatment. (Ad.) Neurite outgrowth was quantified by measuring the total fluorescence at multiple cross-sections of the image. The zero point on the x-axis represents the right edge of microgrooves. All data points were normalized to the first point of "No Axotomy" at 100 µm from the microgrooves as 100 percent. Statistical differences were calculated from two independent experiments using two-way ANOVA. Asterisks show significance compared to Ctrl treatment at a given distance; *, p < 0.05; ***, p < 0.001. Cortical neurons in nonsupplemented neurobasal media were treated with IL-6 and HU-210 or DMSO for controls for 2hours. The cells were lysed and subjected to immunoblot analysis for phospho-STAT3 (p-Tyr705), total STAT3 and βIII-tubulin. We normalized the samples for phospho-STAT3 to total STAT3 and made a bar graph with the fold changes. Using the rat ONC model and retrogradely labeling regenerating axons with Cholera Toxin B (CTB) by intravitreal injections into the retina 3 days prior to sacrificing and then chemical clearing using the 3-DISCO technique, we were visualizing the whole nerve and not just sections using a Multiphoton microscope. Note these images are not to the scale, so they have individual scale bars. Control (A) not treated animals, have few labeled axons crossing a short distance (less than 0.2mm from the crush site), this was consistent for IL-6 (B) and HU-210 (C) tested individually as well, where no significant axonal regeneration was detected past the crush site.
Combining intravitreal injections of IL-6 and HU-210 also promoted limited growth (D). Taxol applied in gelfoam alone had promoted limited axonal regeneration (E). Adding Taxol gelfoam with IL-6 and HU-210 injections resulted in more robust growth, but still less than 1mm from the crush site (F). APC gelfoam alone also promoted modest axonal regeneration from the crush site (G). Slightly more robust growth is detected when we combine IL-6 and HU-210 with APC gelfoam.
